Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vitiligo Clear all
Completed Phase 2 Interventional Results available

Clinical Trial of Simvastatin to Treat Generalized Vitiligo

NCT01517893
View directory record Official record
Conditions
Vitiligo
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
John Harris
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting Phase 2 Interventional

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
GIA632, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Not applicable Interventional

Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo

NCT05238077
View directory record Official record
Conditions
Generalized Vitiligo
Interventions
Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jul 21, 2026, 11:56 AM EDT
Active, not recruiting No phase listed Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
54
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Gut and Skin Microbiome in Vitiligo Disease Progression

NCT03577327
View directory record Official record
Conditions
Vitiligo, Healthy
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Narrowband UVB Treatment in Patients With Vitiligo

NCT00398723
View directory record Official record
Conditions
Vitiligo
Interventions
Narrowband UVB
Device
Lead sponsor
Mary Sullivan-Whalen
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Jul 21, 2026, 11:56 AM EDT
Not listed Phase 1 Interventional

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

NCT02281058
View directory record Official record
Conditions
Vitiligo
Interventions
Abatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

NCT03468855
View directory record Official record
Conditions
Vitiligo
Interventions
ATI-50002 topical solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Encinitas, California • Los Angeles, California • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Jul 21, 2026, 11:56 AM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting No phase listed Observational

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

NCT06491615
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2054
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

NCT05247489
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib 1.5% cream, NB-UVB phototherapy
Drug · Device
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Fountain Valley, California • Sacramento, California • Sunnyvale, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jul 21, 2026, 11:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Research Study Participant Registry

NCT00710489
View directory record Official record
Conditions
Acne, Actinic Keratosis, Dysplastic Nevi, Eczema, Psoriasis, Skin Cancer, Rosacea, Leg Ulcers, Foot Ulcers, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 21, 2026, 11:56 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

NCT06602232
View directory record Official record
Conditions
Alopecia Areata, Vitiligo
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Northridge, California • Miami, Florida • Evans, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands

NCT00622180
View directory record Official record
Conditions
Vitiligo
Interventions
NBUVB, Monochromacitc Excimer light
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Jul 21, 2026, 11:56 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo

NCT01822379
View directory record Official record
Conditions
Vitiligo
Interventions
Melanocyte Keratinocyte transplantation
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 21, 2026, 11:56 AM EDT
Not listed Phase 2 Interventional

Treatment of Hypopigmented Scars With Bimatoprost

NCT06122090
View directory record Official record
Conditions
Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Interventions
Bimatoprost, Saline
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 21, 2026, 11:56 AM EDT
Active, not recruiting Phase 2 Interventional

Daily Topical Rapamycin for Vitiligo

NCT05342519
View directory record Official record
Conditions
Vitiligo
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

NCT00771355
View directory record Official record
Conditions
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

NCT06548360
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

NCT04487860
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
AS012, Placebo
Drug
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 21, 2026, 11:56 AM EDT
Active, not recruiting Phase 1 Interventional

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

NCT06625177
View directory record Official record
Conditions
Vitiligo
Interventions
TEV-53408
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Fremont, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
VYN201 Gel, Vehicle Gel
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

Vitiligo Skin Transplantation

NCT00830713
View directory record Official record
Conditions
Vitiligo
Interventions
Melanocyte-keratinocyte transplantation procedure (MKTP)
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131
View directory record Official record
Conditions
Vitiligo
Interventions
ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment, NB-UVB phototherapy sham treatment
Drug · Device
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Rolling Meadows, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 21, 2026, 11:56 AM EDT